**Description**: The fixed-dose coformulation (FDC) of albendazole and ivermectin is the result of more than 10 years of innovations carried out by African and European organizations working through public-private partnerships.
This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial. The results are already accepted for publication in Lancet Infectious Diseases and are currently under evaluation by the European Medicines Agency (EMA) under the EU-M4All procedure and Ghana's FDA for registration.
This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial. The results are already accepted for publication in Lancet Infectious Diseases and are currently being evaluated by the European Medicines Agency (EMA) under the EU-M4All procedure, and Ghana's FDA for registration.
The fixed-dose combination of albendazole and ivermectin provides a novel approach to mass drug administration campaigns that simplifies logistics while providing control abilities for more parasites. It allows for a more targeted approach
borja
2 months ago